Invitrogen Introduces Multiplex Kit for Stem Cells
CARLSBAD, Calif.--(BUSINESS WIRE)--Oct 8, 2007 - Invitrogen
Corporation (NASDAQ:IVGN)
technologies for research, production and diagnostics, today
announced the launch of a new kit that allows researchers to quickly
and reliably monitor the state of human embryonic stem cells (hESCs).
The STEMPRO(R) EZChek(TM) Multiplex PCR Kit allows scientists to
monitor hESCs with one reaction, using fewer sample cells than ever
before.
The most important characteristic of ESCs is their pluripotency, or
ability to differentiate into all three primitive cell lineages in
the body -- endoderm, ectoderm and mesoderm. Researchers working with
hESCs must continually screen them to ascertain pluripotency. A
preferred monitoring method is the use of polymerase chain reaction
(PCR) to amplify specific markers associated with pluripotency. PCR
is a sensitive and early measurement of differentiation, but it
requires the researcher to sacrifice sample cells, leaving fewer
behind for research purposes.
The STEMPRO(R) EZChek(TM) Kit allows for the analysis of four early
differentiation markers using a small sample and a single-tube
reaction. Without the kit, researchers need to carry out five
separate reactions in five tubes, using many more cells. In addition,
the kit requires no extensive additional training to achieve desired
results.
"The crux of any stem cell researcher's work is the ability to
monitor the differentiation state of hESCs," said Joydeep Goswami,
Vice President, Stem Cells and Regenerative Medicine. "Unfortunately,
current processes are laborious and consume more cells, a precious
scientific resource. STEMPRO(R) EZChek(TM) makes this important step
less time-consuming and less costly and allows researchers to assess
whether the cells remain pluripotent or have differentiated into
endoderm, ectoderm or mesoderm lineages."
Invitrogen is the premier supplier of tools and reagents for stem
cell research. The company offers more than 1,200 products tailored
to various parts of the stem cell research workflow for embryonic and
adult stem cell populations, including Dynabeads(R) for cell
separation; pre-conjugated stem cell antibodies from Molecular
Probes; and gold standard media from GIBCO such as KNOCKOUT(TM) Serum
Replacement and MesenPRO(TM) RS reduced serum medium for mesenchymal
stem cells. The company recently announced the launch of STEMPRO(R)
hESC SFM, a new fully-defined, serum-and feeder-free media
specifically formulated for the growth and expansion of hESCs, and
the STEMPRO(R) EZPassage(TM) tool for stem cell passaging.
About Invitrogen
Invitrogen Corporation (NASDAQ:IVGN) provides products and services
that support academic and government research institutions and
pharmaceutical and biotech companies worldwide in their efforts to
improve the human condition. The company provides essential life
science technologies for disease research, drug discovery, and
commercial bioproduction. Invitrogen's own research and development
efforts are focused on breakthrough innovation in all major areas of
biological discovery including functional genomics, proteomics,
bioinformatics and cell biology -- placing Invitrogen's products in
nearly every major laboratory in the world. Founded in 1987,
Invitrogen is headquartered in Carlsbad, California, and conducts
business in more than 70 countries around the world. The company is
celebrating 20 years of accelerating scientific discovery. Invitrogen
globally employs approximately 4,300 scientists and other
professionals and had revenues of more than $1.15 billion in 2006.
For more information, visit www.invitrogen.
Safe Harbor Statement
Certain statements contained in this press release are
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, and it is
Invitrogen's intent that such statements be protected by the safe
harbor created thereby. Forward-looking statements include, but are
not limited to, those regarding: 1) STEMPRO(R) EZChek(TM) Multiplex
PCR Kit allows researchers to quickly and reliably monitor the
differentiation state of human embryonic stem cells (hESCs); 2) No
extensive training is required to use STEMPRO(R) EZChek(TM); Such
forward-looking statements are subject to a number of risks,
uncertainties and other factors that could cause actual results to
differ materially from future results expressed or implied by such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risks: a) STEMPRO(R) EZChek(TM)
may or may not make stem cell research less time-consuming, and less
costly and b) This may or may not accelerate the important work of
stem cell research; as well as other risks and uncertainties detailed
from time to time in Invitrogen's Securities and Exchange Commission
filings.
Contact
Invitrogen Corporation
Farnaz Khadem, 760-603-7245
farnaz.khadem@
http://www.pharmali
articleid=482153&
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment